Clinical Trials

I am a person who has had to remain in “maintenance” chemo for almost seven years. During this time I have grown to deeply appreciate the caregiving and caring provided at PVHO.

Palo Verde Cancer Specialists is dedicated to providing the most advanced and compassionate cancer care available in the Valley. Our board-certified oncologists, hematologists, and radiation oncologists offer many treatment options giving you the best possible treatment plan. Having all of these specialists and treatment options at one cancer center provides you with a dedicated team to help you overcome cancer.

In addition to current cancer treatments, our oncology center is always working on new therapies to advance cancer treatment. Clinical trials are available for several different types of cancer. Many of our patients want to participate in clinical trials to help in the advancement of treatment options. To learn more about the trials and the criteria to participate, talk to your oncology clinic specialists.

Clinical Trials Available in the Phoenix Area

Myelodysplastic Syndrome:
TetraLogic 0087
A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in combination with 5-azacitidine in patients with Myelodysplastic Syndrome who are Naïve, Refractory, or have Relapsed to 5-azacitidine Therapy.

Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia:
TetraLogic 0094
A Phase 2, randomized, double-blind, placebo-controlled study of Azacitidine with or without Birinapant with a single-arm open-label run-in phase in patients with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.

Pancreatic Cancer:
Incyte INCB18424-362
A randomized, double-blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in combination with Capecitabine in patients with advanced or Metastatic Adenocarcinoma of the Pancreas who have failed or are intolerant to first-line chemotherapy.

Non-Hodgkin Lymphoma:
Infinity IPI-145-06
A Phase 2 Study of IPI-145 in patients with Refractory Indolent Non-Hodgkin Lymphoma.

Triple-Negative Breast Cancer:
Celldex CDX011-04
The study’s primary objective is to evaluate the anti-cancer activity of CDX-011 in metastatic, GPNMB over-expressing, triple-negative breast cancer as measured by the duration of progression-free survival (PFS).

HER2-Positive Breast Cancer:
Merrimack MM-302-02-02-03
Patients with incurable, unresectable, locally advanced/metastatic HER2-positive breast cancer who have received prior treatment with trastuzumab in any setting and who have either progressed on or are intolerant to each of pertuzumab and ado-trastuzumab emtansine in the metastatic or locally advanced setting. Patients must not have been previously treated with an anthracycline in any setting.

Triple-Negative Breast Cancer:
Celgene ABI-007-MBC-001
First-line treatment of patients with triple-negative metastatic breast cancer (TNMBC), defined as estrogen receptor (ER) negative, progesterone receptor (PgR) negative, and human epidermal growth factor receptor 2 (HER2) negative.

Non-Small Cell Lung Cancer:
Celgene ABI-007-NSCL-003
This is a Phase III, randomized, open-label, cross-over, multi-center study of nab-paclitaxel or best supportive care (BSC) as maintenance treatment after response or SD with nab-paclitaxel plus carboplatin as induction in subjects with squamous cell NSCLC. Once a patient in the BSC arm during the Maintenance part of the study experiences radiologic progression of the disease, they will be eligible to cross-over to receive nabpaclitaxel.

Genentech MO22097
An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care ± continuous bevacizumab treatment beyond progression of the disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy.

Talk to Your Oncology Center About Available Clinical Trials Today

If you are interested in learning more about participating in a clinical trial, contact us to schedule an appointment today. Our leading cancer team can answer all of your questions and provide you with more information at any of our five locations.

If you are looking for a leading cancer center in Scottsdale or other surrounding areas, contact us to schedule a consultation. Together, we can work to overcome cancer.

Contact Us Now

SCHEDULE APPOINTMENT or seeking SECOND OPINION? Complete this form and we will contact you within 24-hours.